Groton, CT, United States of America

Alireza S Kord

This inventor holds 1 USPTO granted patent. Top assignee: Pfizer Corporation. Active years: 1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alireza S Kord. Retrieved from https://idiyas.com/inventor/alireza-s-kord

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alireza S. Kord: Inventor in Pharmaceutical Research.

Introduction

Alireza S. Kord is an inventor associated with Groton, Connecticut, and Pfizer Corporation. His patent work concerns a neuropeptide Y ligand salt with potential use in treating physiological disorders.

Latest Patents

The supplied information lists one patent for Kord: “Dimesylate Salts of Neuropeptide Y Ligands.” The patent describes the dimesylate salt of cis-1-(3-ethoxyphenyl)-1-(4-phenylpiperazin-1-yl)-4-methyl-cyclohexane and reports that it has superior properties. The compound is described as useful for treating physiological disorders associated with excess neuropeptide Y. Kord’s listed patent portfolio comprises 1 patent.

Career Highlights

Kord’s listed invention reflects work on pharmaceutical compounds and their potential therapeutic applications. The supplied information associates him with Pfizer Corporation in Groton, Connecticut.

Collaborations

Laurie A. Whipple and Lyle R. Brostrom are identified as Kord’s coworkers. The available information does not specify their roles in the patent or the invention.

Conclusion

Alireza S. Kord’s listed patent focuses on a dimesylate salt of a neuropeptide Y ligand and its potential application in treating disorders associated with excess neuropeptide Y.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…